vTv Therapeutics Inc. - Class A Common Stock (VTVT): Product News News

VTVT – Announces topline results from Part B of Phase 3 STEADFAST Study miss co-primary efficacy endpoints.


Key Facts Surrounding This News Item


  • VTVT had a POWR Rating of D (Sell) coming into today.
  • VTVT was -0.19% below its 10-Day Moving Average coming into today.
  • VTVT was 3.65% above its 20-Day Moving Average coming into today.
  • VTVT was -4.98% below its 50-Day Moving Average coming into today.
  • VTVT was -55.30% below its 100-Day Moving Average coming into today.
  • VTVT was -62.54% below its 200-Day Moving Average coming into today.
  • VTVT had returned -69.88% year-to-date leading up to today’s news, versus a +4.80% return from the benchmark S&P 500 during the same period.

More Info About vTv Therapeutics Inc. – Class A Common Stock (VTVT)


vTv Therapeutics Inc., a biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company was founded in 2015 and is based in High Point, North Carolina. View our full VTVT ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

VTVT at a Glance

VTVT Current POWR Rating™
Overall POWR Rating™
VTVT Current Price $3.28 3.24%
More VTVT Ratings, Data, and News

VTVT Price Reaction

The day of this event (Jun. 12, 2018)
VTVT Closing Price$1.89 4.42%
VTVT Volume451,800
19.51% from avg
Leading up to this event
VTVT 1-mo returnN/A%
After this event
VTVT 1-day return9.70%
VTVT 3-day return2.84%
VTVT 5-day return7.74%

VTVT Price Chart



More vTv Therapeutics Inc. - Class A Common Stock (VTVT) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All VTVT News
Page generated in 0.7361 seconds.